Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Drug

Fosun Pharma’s Generic Remodulin Gains NMPA Approval for Pulmonary Arterial Hypertension

Fineline Cube Mar 17, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its generic...

Company Drug

RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor

Fineline Cube Mar 17, 2023

China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration...

Company Deals

Triastek Partners with Boehringer Ingelheim to Advance 3D Printed Drug Dosage Forms

Fineline Cube Mar 17, 2023

China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with...

Company Drug

ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors

Fineline Cube Mar 16, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...

Company Deals

ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705

Fineline Cube Mar 16, 2023

Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr,...

Company Medical Device

Agena Bioscience’s CYP2C19 Genotyping Kit Gains NMPA Approval for Cardiovascular Applications

Fineline Cube Mar 16, 2023

Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical...

Company

Ping An Life Insurance Reports Steady Profit Growth and Expands Managed Care Services

Fineline Cube Mar 16, 2023

Ping An Life Insurance Company of China Ltd released its 2022 financial report, recording RMB...

Company

Akeso Biopharma Reports 422% Increase in Product Sales, Boosted by Cadonilimab and Penpulimab

Fineline Cube Mar 16, 2023

China-based Akeso Biopharma (HKG: 9926) released its 2022 financial report, highlighting significant growth in product...

Company

CStone Pharmaceuticals Reports 97.54% Revenue Growth in 2022, Driven by Drug Sales and Licensing Fees

Fineline Cube Mar 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) released its 2022 financial report, recording total revenues of RMB...

Company Drug

Henlius’ OX40 Monoclonal Antibody HLX51 Gains NMPA Approval for Phase I Clinical Study

Fineline Cube Mar 16, 2023

Shanghai Henlius Biotech, Inc (HKG: 2696) has announced that it has received approval from the...

Company Deals

Boao Lecheng and Shanghai Biomed Center Form Long-Term Partnership for Medical Innovation

Fineline Cube Mar 16, 2023

The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has entered into a long-term...

Company Drug

Haisco Pharmaceutical’s EGFR-PROTAC HSK40118 Gains NMPA Approval for Clinical Trials

Fineline Cube Mar 16, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received clinical...

Company Drug

Astellas Pharma’s Xtandi Gains Momentum in China with Positive Phase III ARCHES Study Results

Fineline Cube Mar 15, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that its prostate cancer therapy, Xtandi (enzalutamide),...

Company

World Orphan Drug Alliance Expands to China with RareStone Group Partnership

Fineline Cube Mar 15, 2023

The World Orphan Drug Alliance (WODA) has announced its expansion to China for the first...

Company Drug

MabPharm Files NDA for CMAB009, Biosimilar to Erbitux, Targeting Metastatic Colorectal Cancer

Fineline Cube Mar 15, 2023

Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the filing of...

Company Deals

Neowise Biotechnology Secures RMB 200 Million in Series A+ Financing Round

Fineline Cube Mar 15, 2023

Neowise Biotechnology Co., Ltd, a T cell receptor (TCR)-therapy developer based in Suzhou, reportedly raised...

Company Deals

Singde Yiyang Secures Series A Financing to Expand Wellness Services in China

Fineline Cube Mar 15, 2023

Singde Yiyang, a leading wellness service provider based in Qingdao, reportedly raised “hundreds of millions”...

Drug Policy / Regulatory

NMPA Releases 65th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Mar 15, 2023

The National Medical Products Administration (NMPA) has released the 65th batch of reference drugs for...

Hospital Policy / Regulatory

NHSA Launches Crackdown on Medical Insurance Fund Management with New Inspection Measures

Fineline Cube Mar 15, 2023

The National Healthcare Security Administration (NHSA) is intensifying efforts to manage medical insurance funds at...

Company Deals

Meinian Onehealth and Astra Biotechnology Partner on Hypersensitive Blood Biomarker Detection

Fineline Cube Mar 15, 2023

China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with...

Posts pagination

1 … 487 488 489 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.